BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 24783502)

  • 1. [Recent advances in the study of mechanism of APOBEC3G against virus].
    Zhu YP; Jiang JD; Peng ZG
    Yao Xue Xue Bao; 2014 Jan; 49(1):30-6. PubMed ID: 24783502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
    Fan B; Cen S; Jiang JD
    Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
    Feng Y; Love RP; Chelico L
    J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent.
    Browne EP; Allers C; Landau NR
    Virology; 2009 May; 387(2):313-21. PubMed ID: 19304304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G.
    Sugiyama R; Nishitsuji H; Furukawa A; Katahira M; Habu Y; Takeuchi H; Ryo A; Takaku H
    J Biol Chem; 2011 Mar; 286(12):10051-7. PubMed ID: 21228271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.
    Gillick K; Pollpeter D; Phalora P; Kim EY; Wolinsky SM; Malim MH
    J Virol; 2013 Feb; 87(3):1508-17. PubMed ID: 23152537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV Restriction Factor APOBEC3G and Prospects for Its Use in Gene Therapy for HIV].
    Tikhonov AS; Mintaev RR; Glazkova DV; Bogoslovskaya EV; Shipulin GA
    Mol Biol (Mosk); 2022; 56(4):546-556. PubMed ID: 35964311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.
    Farrow MA; Sheehy AM
    Future Microbiol; 2008 Apr; 3(2):145-54. PubMed ID: 18366335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.
    Haché G; Shindo K; Albin JS; Harris RS
    Curr Biol; 2008 Jun; 18(11):819-24. PubMed ID: 18501607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Death by deamination: a novel host restriction system for HIV-1.
    Goff SP
    Cell; 2003 Aug; 114(3):281-3. PubMed ID: 12914693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
    Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
    J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
    Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
    Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
    Franca R; Spadari S; Maga G
    Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein.
    Chaurasiya KR; McCauley MJ; Wang W; Qualley DF; Wu T; Kitamura S; Geertsema H; Chan DS; Hertz A; Iwatani Y; Levin JG; Musier-Forsyth K; Rouzina I; Williams MC
    Nat Chem; 2014 Jan; 6(1):28-33. PubMed ID: 24345943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytidine deaminases as a weapon against retroviruses and a new target for antiviral therapy.
    Izumi T; Shirakawa K; Takaori-Kondo A
    Mini Rev Med Chem; 2008 Mar; 8(3):231-8. PubMed ID: 18336343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms for inhibition of retrovirus replication by APOBEC3 family].
    Iwatani Y
    Uirusu; 2011 Jun; 61(1):67-72. PubMed ID: 21972557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.